Abstract

The tumor microenvironment (TME) is a complex multicellular functional compartment that includes fibroblasts, myofibroblasts, endothelial cells, immune cells, and extracellular matrix (ECM) elements. The microenvironment provides an optimum condition for the initiation, growth, and dissemination of hepatocellular carcinoma (HCC). As one of the critical and abundant components in tumor microenvironment, cancer-associated fibroblasts (CAFs) have been implicated in the progression of HCC. Through secreting various growth factors and cytokines, CAFs contribute to the ECM remodeling, stem features, angiogenesis, immunosuppression, and vasculogenic mimicry (VM), which reinforce the initiation and development of HCC. In order to restrain the CAFs-initiated HCC progression, current strategies include targeting specific markers, engineering CAFs with tumor-suppressive phenotype, depleting CAFs’ precursors, and repressing the secretions or downstream signaling. In this review, we update the emerging understanding of CAFs in HCC, with particular emphasis on cellular origin, phenotypes, biological functions and targeted strategies. It provides insights into the targeting CAFs for HCC treatment.

Highlights

  • Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide [1]

  • According to the latest statistics, almost 85% of HCC cases occur in developing countries such as Eastern Asia and subSaharan Africa, where chronic hepatitis B virus (HBV) is the most common etiology [2, 3]

  • Accumulating evidences suggest the pivotal roles of cancer-associated fibroblasts (CAFs) in favoring aggressive behaviors in HCC

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide [1]. Zhou et al indicated that HCC-derived exosomal miRNA-21 could induce the conversion of HSCs into CAFs via downregulating PTEN and activating PDK1/ AKT signaling pathway, subsequently accelerating tumor growth and angiogenesis by secreting massive proinflammatory cytokines [40].

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.